Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 3,872 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: FAST Clear all

Conditions: Lung Transplantation, Respiratory Tract Infections, Pulmonary Infection
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Respiratory Rate Monitoring
Interventions: Physiological Monitoring with SpO₂ Sensors and Capnography; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 4 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Trauma Injury, Hemorrhage
Interventions: Bleeding Control Basic (B-Con) Course; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infectious Disease, Drug Effect, Clinical Infection
Interventions: Azithromycin Oleogel (Oral and Rectal); Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Respiratory Failure
Interventions: Rapid sequence intubation: sedative first, Rapid sequence intubation: paralytic first; Other
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Kidney Transplantation
Interventions: Myfortic; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: HIV Infections
Interventions: GSK3810109A, Dolutegravir+lamivudine SOC regimen; Biological
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Long Beach, California • Los Angeles, California • Orlando, Florida + 3 more

Conditions: Healthy Participants
Interventions: AZD8965, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 147 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Renal Impairment, Disease Severity
Interventions: Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee

Conditions: Mild Cognitive Impairment, Alzheimer Disease, Alzheimer's Disease
Interventions: Time-restricted eating; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy Volunteer
Interventions: GDC-0980, rabeprazole; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Substance-related Disorders
Interventions: On-site bundled rapid HIV/HCV testing, Standard of care (SOC); Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Fanconi Anemia
Interventions: Bone Marrow Aspiration, Filgrastim, Genetically Engineered Hematopoietic Stem Progenitor Cells, Laboratory Biomarker Analysis, Leukapheresis, Methylprednisolone, Plerixafor, Prednisone; Procedure · Biological · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 4 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sleep, Consolidation
Interventions: Targeted memory reactivation (odors), Targeted memory reactivation (sounds); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Surgical Incision, Nose Deformity
Interventions: Closure with Permanent Suture, Closure with Resorbable Suture; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 99 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Charleston, South Carolina

Conditions: Cancer
Interventions: Time-restricted eating, Questionnaire Administration, Biospecimen Collection, Health coaching; Behavioral · Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 2 Diabetes, Obesity
Interventions: discontinuation of sugar sweetened beverages; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Volunteer
Interventions: ABBV-932; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Non-Insulin-dependent Diabetes Mellitus
Interventions: placebo, 3.4 g psyllium BID, 6.8g psyllium BID; Dietary Supplement
Lead sponsor: Procter and Gamble; Industry
Eligibility: 36 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1988 – 1990
U.S. locations: 2
States / cities: Miami, Florida • Minneapolis, Minnesota

Conditions: Infant, Newborn, Disease, Genetic Disease
Interventions: Neonate WGS Testing; Diagnostic Test
Lead sponsor: Jerry Vockley, MD, PhD; Other
Eligibility: Up to 1 Year
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy Volunteers
Interventions: TAK-935 Tablets, TAK-935 Oral Solution; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Glendale, California

Conditions: Type 2 Diabetes
Interventions: Lixisenatide (AVE0010), Insulin glulisine QD, Insulin glulisine TID, Insulin Glargine (Mandatory background drug), Metformin (Background drug); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 46
States / cities: Sun City, Arizona • Tempe, Arizona • Little Rock, Arkansas + 41 more

Conditions: Brain Metastases, Adult, Brain Tumor - Metastatic, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Extra-cranial Solid Tumors
Interventions: Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV; Radiation
Lead sponsor: Ayal A. Aizer, MD; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rapidly Escalating Migraine
Interventions: DFN-11; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Springfield, Missouri

Search by objective public record fields.

Rapid Detection of Airway Pathogens for Lung Transplantation

Respiration From Pleth Validation

Tourniquet Training Effectiveness Study

A Single-Dose, Three-Way, Three-Sequence, Crossover BA Study of Azithromycin Oleogel

Drug Order for Rapid Sequence Intubation

Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State

A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants

A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects

TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet

A Bundled Rapid HIV/HCV Testing Intervention to Increase Receipt of Test Results

Gene Therapy for Fanconi Anemia

Reactivating Specific Memories During Sleep in Conjunction with a Suppression Context

Rhinoplasty Scar Comparison

Effect of Meal Timing During Adjuvant Treatment for Cancer

Effect of Discontinuation of Sugar Sweetened Beverages

A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants

Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects

Genome Sequencing in the Intensive Care Unit Population

A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction

Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine